Please provide your email address to receive an email when new articles are posted on . The American College of Cardiology Scientific Session will take place April 6 to 8 in Atlanta. This year also ...

Please provide your email address to receive an email when new articles are posted on . Return-to-play considerations and CVD risks of people who perform under life-threatening conditions were among ...

SAN DIEGO, CA—Networking with purpose, learning to say yes—and also no—and thinking creatively were the key messages presented to fellows and early career cardiologists attending the “Careers in ...

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor’s technology at the ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address ...

Results from the ODYSSEY Outcomes trial for the PCSK9 inhibitor alirocumab were the top news at the meeting. The American College of Cardiology (ACC) held its 67th Scientific Session March 10-12, 2018 ...

Highlights from the American College of Cardiology's 2020 Annual Scientific Session Together With World Congress of Cardiology virtual conference, which took place on March 28-30, 2020. Stay ahead of ...

Cangrelor, an intravenous potent, rapid-acting P2Y12 inhibitor, reduces the risk of early ischemic events compared with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary ...

Atorvastatin was associated with a significant improvement in estimated glomerular filtration rates as well as a significant reduction in hospitalizations for congestive heart failure, according to ...